Conference Coverage

Sleep EEG may predict later antidepressant response


 

FROM ECNP 2020

Study could have “enormous implications”

Of note, in the landmark National Institute of Mental Health–sponsored Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, slightly less than half of patients with major depressive disorder achieved a treatment response to their first-line antidepressant, and it took an average of 6 weeks of therapy to do. About one in four nonresponders who chose to switch to a different antidepressant got better.

Dr. Catherine Harmer

“The STAR*D trial is still the gold standard for understanding antidepressant response, and so being able to see if an antidepressant works within 1 week would be a real breakthrough,” Catherine Harmer, DPhil, said in an interview.

“Most of the time, patients need to wait for around 4 weeks before they can tell if they are responding to a particular antidepressant or not. This is a hugely disabling and lengthy process, and often a different treatment then needs to be started,” added Dr. Harmer, professor of cognitive neuroscience and director of the Psychopharmacology and Emotional Research Lab at the University of Oxford (England).

“If the study results presented by Dr. Mikoteit are replicated in a larger blinded study, then it would have enormous implications for the future treatment of individuals with depression,” according to Dr. Harmer, who was not involved in the study and has no conflicts of interest related to it.

Dr. Mikoteit reported having no financial conflicts regarding the study, funded by the Psychiatric University Hospital of Basel.

SOURCE: Mikoteit T et al. ECNP 2020, Abstract P.733.

Pages

Recommended Reading

COVID-19 and Mental Health Awareness Month
Journal of Clinical Outcomes Management
COVID-19: Psychiatrists assess geriatric harm from social distancing
Journal of Clinical Outcomes Management
Domestic violence amid COVID-19: Helping your patients from afar
Journal of Clinical Outcomes Management
COVID-19 ravaging the Navajo Nation
Journal of Clinical Outcomes Management
Human sitters in the COVID era
Journal of Clinical Outcomes Management
Beefed up inpatient/outpatient care transition is key to suicide prevention
Journal of Clinical Outcomes Management
‘Staggering’ increase in COVID-linked depression, anxiety
Journal of Clinical Outcomes Management
FDA okays new indication for esketamine nasal spray
Journal of Clinical Outcomes Management
Nine antihypertensive drugs associated with reduced risk of depression
Journal of Clinical Outcomes Management
COVID-19: New guidance to stem mental health crisis in frontline HCPs
Journal of Clinical Outcomes Management